NEW YORK, Sept. 24 – Solexa, a UK-based developer of high-throughput technology, has closed on roughly $12 million in its second round of venture capital financing, the company said on Monday.

Nick McCooke, Solexa's president and managing director, told GenomeWeb that the cash will be used to help create “the next generation of DNA sequencing tools.” McCooke reckons this recent cash infusion should be enough help the company meet that goal, which he said would likely happen within two years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.